Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.53

-1.6324 (-9.51%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

11:02
11/30/16
11/30
11:02
11/30/16
11:02

Takeda could be 'lured back' if Valeant increases Salix disclosures, FT says

After the Wall Street Journal reported that Valeant (VRX) and Takeda Pharmaceutical (TKPYY)have come to an impasse over the potential price of Salix in a sale, Financial Times reports that a person briefed about the deal said that Takeda "could be lured back to the table" if Valeant discloses more information about Salix's financials and business. Valeant shares are off their earlier lows, but remain down about 8% near 11 am ET. Reference Link

VRX

Valeant

$15.53

-1.6324 (-9.51%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

VRX Valeant
$15.53

-1.6324 (-9.51%)

11/18/16
DBAB
11/18/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche still likes near-term setup for Valeant shares
Deutsche Bank analyst Gregg Gilbert said yesterday that he still likes the near-term setup for shares of Valeant Pharmaceuticals after federal prosecutors announced criminal charges against former executive Gary Tanner and the former CEO of Philidor. It is "good to see" that Valeant and other senior executives were not charged, Gilbert told investors in a research note. The charges could be an important step forward as the company and new management team distance themselves from the past, Gilbert wrote. The analyst points out that the bar for 2016 has already been lowered and that new CFO Paul Herendeen thinks of guidance as a commitment. Gilbert keeps a Hold rating on Valeant with a $24 price target. The stock closed yesterday up 12c to $17.98.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
TKPYY Takeda Pharmaceutical Co. Ltd.
$20.97

-0.035 (-0.17%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

LLY

Eli Lilly

$83.42

1.53 (1.87%)

06:27
04/25/17
04/25
06:27
04/25/17
06:27
Earnings
Eli Lilly reports Q1 EPS 98c, consensus 96c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

WEGRY

Weir Group

$12.91

0.71 (5.82%)

06:27
04/25/17
04/25
06:27
04/25/17
06:27
Upgrade
Weir Group rating change  »

Weir Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$79.37

0.72 (0.92%)

06:26
04/25/17
04/25
06:26
04/25/17
06:26
Hot Stocks
Breaking Hot Stocks news story on DuPont »

DuPont up 2.1% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FOX

21st Century Fox

$29.75

-0.47 (-1.56%)

, FOXA

21st Century Fox

$30.35

-0.35 (-1.14%)

06:25
04/25/17
04/25
06:25
04/25/17
06:25
Periodicals
Former presenter names Fox News executives in new lawsuit, FT says »

Andrea Tantaros, a former…

FOX

21st Century Fox

$29.75

-0.47 (-1.56%)

FOXA

21st Century Fox

$30.35

-0.35 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 15

    Jun

CTSH

Cognizant

$58.89

1.04 (1.80%)

06:24
04/25/17
04/25
06:24
04/25/17
06:24
Recommendations
Cognizant analyst commentary  »

Cognizant fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

  • 09

    May

  • 12

    May

  • 31

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

ST

Sensata

$42.76

1.71 (4.17%)

06:16
04/25/17
04/25
06:16
04/25/17
06:16
Earnings
Sensata sees FY17 adjusted EPS $3.08-$3.20, consensus $3.14 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 09

    May

PRGS

Progress Software

$29.73

0.24 (0.81%)

06:16
04/25/17
04/25
06:16
04/25/17
06:16
Hot Stocks
Progress Software appoints Dmitri Tcherevik to Chief Technology Officer »

Progress announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:15
04/25/17
04/25
06:15
04/25/17
06:15
General news
FX Action: EUR-JPY rallied to a fresh one-month peak »

FX Action: EUR-JPY…

ST

Sensata

$42.76

1.71 (4.17%)

06:13
04/25/17
04/25
06:13
04/25/17
06:13
Earnings
Sensata sees Q2 adjusted EPS 70c-80c, consensus 81c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 09

    May

GIII

G-III Apparel

$24.35

0.76 (3.22%)

, SMRT

Stein Mart

06:13
04/25/17
04/25
06:13
04/25/17
06:13
Periodicals
Stein Mart selling Ivanka Trump clothing under different label, WSJ reports »

Ivanka Trump clothing was…

GIII

G-III Apparel

$24.35

0.76 (3.22%)

SMRT

Stein Mart

JWN

Nordstrom

$47.23

-0.39 (-0.82%)

M

Macy's

$29.19

-0.29 (-0.98%)

DDS

Dillard's

$54.38

0.44 (0.82%)

TJX

TJX

$78.62

0.06 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

TECK

Teck Resources

$21.96

0.17 (0.78%)

06:13
04/25/17
04/25
06:13
04/25/17
06:13
Earnings
Teck Resources reports Q1 EPS C$1.16 vs. C$0.03 last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

PPG

PPG

$108.01

2.07 (1.95%)

, AKZO

Akzo Nobel

06:13
04/25/17
04/25
06:13
04/25/17
06:13
Periodicals
Dutch Economic Affairs Minister still opposes Akzo Nobel takeover, Reuters says »

Dutch Economic Affairs…

PPG

PPG

$108.01

2.07 (1.95%)

AKZO

Akzo Nobel

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ST

Sensata

$42.76

1.71 (4.17%)

06:12
04/25/17
04/25
06:12
04/25/17
06:12
Earnings
Sensata reports Q1 adjusted EPS 71c, consensus 68c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 09

    May

AMZN

Amazon.com

$907.41

8.88 (0.99%)

06:10
04/25/17
04/25
06:10
04/25/17
06:10
Downgrade
Raymond James downgrades Amazon with shares up 21% this year »

Raymond James analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 23

    May

PPBI

Pacific Premier

$36.75

0.7 (1.94%)

06:10
04/25/17
04/25
06:10
04/25/17
06:10
Earnings
Pacific Premier reports Q1 EPS 34c, consensus 42c »

First quarter results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

RDWR

Radware

$15.42

0.25 (1.65%)

06:10
04/25/17
04/25
06:10
04/25/17
06:10
Hot Stocks
Radware reports cash and equivalents $316M as of March 31 »

As of March 31 the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

06:10
04/25/17
04/25
06:10
04/25/17
06:10
General news
FX Action: EUR-JPY rallied to a fresh one-month peak »

FX Action: EUR-JPY…

CAPR

Capricor Therapeutics

$3.09

0.08 (2.66%)

06:09
04/25/17
04/25
06:09
04/25/17
06:09
Hot Stocks
Capricor announces 'positive' six-month results from Phase I/II HOPE trial »

Capricor Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

RDWR

Radware

$15.42

0.25 (1.65%)

06:09
04/25/17
04/25
06:09
04/25/17
06:09
Hot Stocks
Radware approves new $40M repurchase plan »

Radware announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

DFRG

Del Frisco's

06:08
04/25/17
04/25
06:08
04/25/17
06:08
Hot Stocks
Del Frisco's to open two restaurants in FY17, four to seven in FY18 »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    May

RDWR

Radware

$15.42

0.25 (1.65%)

06:08
04/25/17
04/25
06:08
04/25/17
06:08
Earnings
Radware reports Q1 non-GAAP EPS 2c, consensus 1c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

FNB

F.N.B.

$14.53

0.19 (1.33%)

06:07
04/25/17
04/25
06:07
04/25/17
06:07
Earnings
F.N.B. reports Q1 operating EPS 23c, consensus 22c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 17

    May

DFRG

Del Frisco's

06:07
04/25/17
04/25
06:07
04/25/17
06:07
Earnings
Del Frisco's raises FY17 adjusted EPS view to 82c-86c from 80c-84c »

FY17 consensus 84c. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    May

YHOO

Yahoo

$48.15

0.63 (1.33%)

, VZ

Verizon

$47.05

-0.2 (-0.42%)

06:07
04/25/17
04/25
06:07
04/25/17
06:07
Periodicals
Yahoo CEO Mayer to have big payday after Verizon deal, NY Times reports »

Yahoo (YHOO) CEO Marissa…

YHOO

Yahoo

$48.15

0.63 (1.33%)

VZ

Verizon

$47.05

-0.2 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

EBF

Ennis

06:06
04/25/17
04/25
06:06
04/25/17
06:06
Earnings
Ennis reports Q4 cont ops EPS 28c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.